INTEGRATED BIOPHARMA INC (INBP): Entry into a Material Definitive Agreement
INTEGRATED BIOPHARMA INC (INBP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.2 3 ex_983424.htm EXHIBIT 10.2 CONVERTIBLE LINE OF CREDIT NOTE ex_983424.htm Exhibit 10.2 Convertible Line of Credit Note (Daily SOFR) $250,000.00 June 30, 2026 FOR VALUE RECEIVED , INTEGRATED BIOPHARMA, INC. , with an address at 225 LONG AVE, STE 15, HILLSIDE, NEW JERSEY 0
- Instrument
- Convertible Line of Credit Note (Daily SOFR)
- Amount
- $250,000.00
- Interest rate
- 2.50%
- Maturity
- April 14, 2027
- Lender
- PNC Bank, National Association
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The disclosed credit facility introduces new debt financing with SOFR-based interest pricing and a conversion to an amortizing term loan after a defined conversion date (earlier of 12 months or a borrower notice). This can influence expectations for cash runway, interest expense, and balance-sheet risk.
Market read
New, company-specific financing terms are disclosed, which can move the stock if investors reassess liquidity and credit risk.
What to watch
Traders may need the full exhibit details (covenants, fees, events of default, and whether conversion is optional) to judge credit risk and equity dilution/overhang implications.
Background
The filing is an SEC Form 8-K reporting entry into a material definitive agreement and termination of another, with an exhibit describing a convertible line of credit note.
Ticker impact
INTEGRATED BIOPHARMA entered a material definitive agreement for a $250,000 convertible line of credit with PNC, converting to a term loan.
Likely modest, sentiment-neutral reaction unless investors view the terms as costly or signal funding stress.
This is a primary-source financing disclosure, but the excerpt provides limited detail on use of proceeds, covenants, and conversion mechanics beyond the stated interest and conversion timing.
Market effects
Adds a datapoint on small-cap biotech/pharma reliance on bank credit and SOFR-linked funding structures.
No clear regional spillover beyond US bank/credit markets.
Limited; financing terms are company-specific and small in scale.
Counterpoint
The facility size is small ($250k), so the market may treat it as routine liquidity management rather than a distress signal.
Key entities
- companyINTEGRATED BIOPHARMA, INC.
Subject of the 8-K; borrower under a $250,000 convertible line of credit note.
- lenderPNC BANK, NATIONAL ASSOCIATION
Bank providing the convertible line of credit facility to the borrower.
